Catalog No.
Product Name
Application
Product Information
Citations
-
Drug-Linker Conjugates for ADC
DBCO-PEG4-VA-PBD is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound utilizes the potent antitumor antibiotic Pyrrolobenzodiazepine (PBD), which is linked via a DBCO-PEG4-VA spacer. DBCO-PEG4-VA-PBD acts as a click chemistry reagent, featuring a DBCO moiety that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. This functionality supports the development of targeted therapies for cancer treatment, enhancing the efficacy of ADCs. -
Drug-Linker Conjugates for ADC
endo-BCN-PEG4-Val-Cit-PAB-MMAE is a cleavable linker specifically designed for antibody-drug conjugates (ADCs), facilitating the targeted delivery of therapeutic agents. This compound features a 4-unit polyethylene glycol (PEG) chain and incorporates a BCN group that enables efficient strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. Its versatility is highly applicable in the development of ADCs, enhancing the efficacy and specificity of cancer therapies. -
Drug-Linker Conjugate for ADC
Val-Ala-PABC-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring a cleavable Tesirine linker (Val-Ala-PABC) coupled with Exatecan, a potent topoisomerase I inhibitor. This conjugate facilitates targeted delivery of cytotoxic agents, making it suitable for the synthesis of various ADC molecules, such as Mal-PEGn-amide-va-Exatecan. Its ability to selectively release the active drug upon internalization enhances therapeutic efficacy against cancer cells. -
Drug-Linker Conjugates for ADC
Val-Ala-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugates (ADCs), comprising the valine-alanine-PAB linker and the cytotoxic agent MMAE. MMAE acts primarily as a potent inhibitor of tubulin, disrupting microtubule dynamics and effectively inducing apoptosis in cancer cells. This reagent is utilized in the development and characterization of ADCs for targeted cancer therapies, enhancing specificity and reducing systemic exposure. -
Drug-Linker Conjugate for ADC
DM21 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). It features a maytansinoid microtubule-disrupting payload linked through a stable tripeptide linker, enhancing its therapeutic efficacy. DM21 is conjugated with a humanized antibody targeting ADAM9, resulting in the formulation of IMGC936, which holds promise in cancer research and targeted therapies. -
Drug-Linker Conjugate for ADC
Mal-PEG4-VA-PBD is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It utilizes the potent antitumor antibiotic Pyrrolobenzodiazepine (PBD), which is covalently linked through Mal-PEG4-VA. This compound facilitates targeted delivery of PBD to tumor cells, enhancing therapeutic efficacy while minimizing off-target effects. Mal-PEG4-VA-PBD is ideal for research into ADC development and optimization in cancer therapy. -
Drug-Linker Conjugates for ADC
TL033 TFA is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a linker that connects bioactive small molecule toxins, facilitating targeted delivery of cytotoxic agents. When conjugated with the Sacituzumab antibody (anti-Trop-2), TL033 TFA enables the synthesis of BT001021, which demonstrates potent anti-cancer activity across various malignancies, including breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer. -
Drug-Linker Conjugates for ADC
Py-MAA-Val-Cit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring the potent cytotoxic agent MMAE. This compound facilitates the synthesis of Zapadcine-3a, which selectively targets TRAILR2. Zapadcine-3a exhibits broad-spectrum anti-tumor activity, effectively inducing apoptosis in TRAILR2-positive tumors. This makes Py-MAA-Val-Cit-PAB-MMAE a valuable tool for advancing targeted cancer therapeutics. -
Drug-Linker Conjugate for ADC
Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Br functions as a drug-linker conjugate for antibody-drug conjugate (ADC) applications. This compound facilitates the synthesis of various therapeutic agents, including ABBV-154, ABBV-927, and ABBV-368, by effectively targeting the glucocorticoid receptor. Its utility in ADC development makes it a valuable reagent for researchers focused on innovative treatment strategies in oncology and immunology. -
Drug-Linker Conjugate for ADC
Amino-PEG4-GGFG-Dxd is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features Dxd as the active drug component linked via a PEG4 spacer, facilitating effective conjugation to antibodies. Amino-PEG4-GGFG-Dxd is suitable for the synthesis of ADCs, providing a versatile tool for targeted cancer therapy research. -
Drug-Linker Conjugate for ADC
MMAE-SMCC is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It consists of the potent mitotic inhibitor Monomethyl Auristatin E (MMAE) conjugated through a stable SMCC linker. This compound targets microtubule dynamics, effectively inhibiting cell division in cancer cells. MMAE-SMCC serves as a valuable tool in the development of targeted cancer therapies, allowing for selective delivery of cytotoxic agents to tumor cells. -
Drug-Linker Conjugates for ADC
Propargyl-PEG4-GGFG-DXd is a drug-linker conjugate specifically designed for antibody-drug conjugate (ADC) applications. This compound includes a PEG-based linker that facilitates the delivery of the DNA topoisomerase I inhibitor DXd. Propargyl-PEG4-GGFG-DXd is utilized in research for targeted cancer therapy, enabling precise drug delivery to tumor cells while minimizing off-target effects. -
Drug-Linker Conjugate for ADC
Val-Cit-PAB-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a DNA topoisomerase I inhibitor, DX-8951, linked via a cathepsin-cleavable linker, Val-Cit-PAB. Its primary mechanism involves targeted delivery of the cytotoxic agent to cancer cells, thereby enhancing therapeutic efficacy while minimizing systemic toxicity. Val-Cit-PAB-Exatecan is utilized in research focused on developing effective ADC therapies for various malignancies. -
Drug-Linker Conjugate for ADC
MC-GGFG-PAB-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound facilitates the selective delivery of cytotoxic agents to targeted cells, enhancing therapeutic efficacy while minimizing off-target effects. It is instrumental in the development of ADCs for cancer treatment research and other therapeutic applications. -
Drug-Linker Conjugates for ADC
SN38-COOH is a key component for the synthesis of antibody-drug conjugates (ADCs). It serves as a functionalized form of SN-38, an active metabolite of the Topoisomerase I inhibitor Irinotecan, which effectively inhibits DNA and RNA synthesis in target cells. This compound is utilized in research focused on targeted cancer therapies, allowing for the precise delivery of cytotoxic agents to improve therapeutic efficacy while minimizing systemic toxicity. -
Drug-Linker Conjugate for ADC
Mal-Val-Ala-PAB-N(SO2Me)-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines the cytotoxic agent Exatecan with a specialized linker, enabling targeted delivery to cancer cells. Mal-Val-Ala-PAB-N(SO2Me)-Exatecan is utilized in the synthesis of FZ-AD005, an ADC targeting delta-like ligand 3 (DLL3) with a binding affinity of 58.3 pM, which demonstrates significant antitumor activity against small cell lung cancer (SCLC). -
Drug-Linker Conjugate for ADC
DBM-MMAF is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs), featuring the potent antitubulin agent MMAF combined with the DBM linker. This compound exerts significant cytotoxic activity through microtubule disruption, facilitating targeted delivery of therapeutic agents to cancer cells. DBM-MMAF is utilized in research applications focused on ADC development and the study of targeted cancer therapies. -
Drug-Linker Conjugate for ADC
DBM-C5-VC-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It consists of a C5-VC-PAB linker coupled with a maleimide functional group and the potent cytotoxic agent MMAE. This conjugate is utilized in targeted cancer therapies, enhancing the selective delivery of MMAE to tumor cells while minimizing systemic exposure. Its unique structural components facilitate effective conjugation to antibodies, paving the way for innovative approaches in oncology research. -
Drug-Linker Conjugates for ADC
MCC-DM1 is a potent drug-linker conjugate targeting antibody-drug conjugates (ADCs) such as Anti-CD22-MCC-DM1. This compound is designed to facilitate selective delivery of cytotoxic agents to target cells, enhancing therapeutic efficacy while minimizing systemic toxicity. MCC-DM1 can be detected in various biological matrices, including rat and human plasma, feces, and other tissues, making it suitable for pharmacokinetic and bioavailability studies in clinical research applications. -
Drug-Linker Conjugate for ADC
XMT-1519 conjugate-1 is a drug-linker conjugate designed for use in antibody-drug conjugate (ADC) applications. This compound facilitates the conjugation with the HER-2 monoclonal antibody Calotatug (XMT-1519), enabling the targeted delivery of therapeutic agents to cancer cells that express the HER-2 receptor. It is an essential component for the synthesis of ADCs aimed at enhancing anticancer efficacy while minimizing off-target effects. -
Drug-Linker Conjugate for ADC
Ac-Lys-Val-Cit-PABC-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound consists of the linker peptide Ac-Lys-Val-Cit-PABC, which facilitates the selective delivery of the potent microtubule inhibitor MMAE, known for its ability to disrupt tubulin polymerization. Ideal for ADC research applications, it supports studies focused on targeted cancer therapies and the mechanism of action of ADCs. -
Drug-Linker Conjugate for ADC
MC-DM1 is a drug-linker conjugate that combines the potent microtubule-disrupting agent DM1 with the stable linker MC, designed for application in antibody-drug conjugates (ADCs). This compound effectively facilitates targeted delivery of cytotoxic agents to malignant cells, thereby enhancing therapeutic efficacy while minimizing off-target effects. MC-DM1 is suitable for research focused on cancer treatment and the development of next-generation ADCs. -
Drug-Linker Conjugate for ADC
DM4-SMCC is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, utilizing the potent antitubulin agent DM4. This conjugate exhibits significant antitumor activity by employing the non-cleavable SMCC linker to facilitate targeted delivery to cancer cells. DM4-SMCC is essential for research involving ADC development and the exploration of targeted cancer therapies. -
Drug-linker Conjugate for ADC
P5(PEG24)-VC-PAB-Exatecan is a drug-linker conjugate that combines the potent DNA Topoisomerase I inhibitor, Exatecan, with the P5(PEG24)-VC-PAB linker, designed for use in antibody-drug conjugate (ADC) applications. This compound demonstrates significant cytotoxicity against tumor cells, making it a valuable tool for cancer research and development. Its unique structure facilitates targeted delivery of Exatecan, enhancing therapeutic efficacy while minimizing off-target effects. -
Drug-Linker Conjugate for ADC
MAL-di-EG-Val-Cit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It combines a specialized linker (MAL-di-EG-Val-Cit-PAB) with MMAE, a potent tubulin inhibitor, to enable targeted delivery of cytotoxic agents to cancer cells. This compound is utilized in research focused on developing more effective ADCs for cancer therapy by minimizing off-target effects and enhancing therapeutic efficacy. -
Drug-Linker Conjugate for ADC
Mal((3S,3aR,6S,6aR)-Hexahydrofuro[3,2-b]furan-3,6-diamine-PEG12)-β-Glu-PAB-Exatecan is a sophisticated drug-linker conjugate that targets DNA Topoisomerase I with the potent inhibitor Exatecan. This compound is designed for use in antibody-drug conjugates (ADCs), providing enhanced specificity and efficacy in cancer therapy. Its unique linker structure facilitates the stable attachment of therapeutic agents to antibodies, improving targeting and reducing systemic toxicity in research applications. -
Drug-Linker Conjugate for ADC
DBCO-PEG4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). It combines the DBCO-PEG4-VC-PAB linker with the potent cytotoxin DMEA-PNU-159682, which includes active metabolites of nemorubicin. This compound leverages click chemistry, featuring a DBCO group that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. DBCO-PEG4-VC-PAB-DMEA-PNU-159682 serves as an effective tool in targeted cancer therapy research and the development of innovative ADCs. -
Drug-Linker Conjugate for ADC
Gly-Gly-Phe-Gly-NH-O-CO-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, comprising a linker moiety and Exatecan, a potent topoisomerase I inhibitor. This compound facilitates the synthesis of ADC molecules, enabling targeted delivery of cytotoxic agents to tumor cells while minimizing off-target effects. Its unique structure allows for effective internalization and release of the active drug in the cellular environment, making it valuable for studies in cancer therapeutics and drug development. -
Drug-Linker Conjugates for ADC
Biotin-PEG7-Maleimide is a biotinylation reagent designed for conjugation with thiol groups (SH). This compound serves as a versatile linker in drug-linker conjugates for antibody-drug conjugates (ADCs), facilitating efficient targeting and delivery of therapeutic agents. Its unique structure allows for enhanced stability and bioavailability in various research applications. -
Drug-Linker Conjugate for ADC
2-MSP-5-HA-GGFG-NH-CH2-O-CH2-CO-Exatecan is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring a cleavable linker bonded to Exatecan. This compound facilitates targeted delivery of cytotoxic agents by linking to anti-Her3 antibodies, enabling enhanced therapeutic efficacy against Her3-expressing tumors. It is a valuable tool for researchers focusing on ADC development and cancer therapy. -
Drug-Linker Conjugates For ADC
TL033 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It comprises a linker and a bioactive small molecule toxin, enabling its conjugation with Sacituzumab, an anti-Trop-2 antibody, to synthesize BT001021. BT001021 exhibits anti-cancer activity against various malignancies, including breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer, making it a valuable tool for cancer research and therapeutic development. -
Drug-Linker Conjugate for ADC
CB07-Exatecan is a drug-linker conjugate specifically designed for antibody-drug conjugate (ADC) synthesis. This conjugate demonstrates potent anti-cancer activity by inhibiting the growth of HER2-positive cancer cells when used in combination with trastuzumab. CB07-Exatecan is a valuable tool for researchers investigating targeted cancer therapies and the development of ADCs in oncology. -
Drug-Linker Conjugate for ADC
BCN-HS-PEG2(vcPABC-MMAE)2 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound incorporates a cleavable linker and the microtubule inhibitor MMAE, facilitating targeted delivery of cytotoxic agents to cancer cells. BCN-HS-PEG2(vcPABC-MMAE)2 is vital for researchers involved in the development and synthesis of ADCs, enhancing therapeutic efficacy while minimizing systemic toxicity. -
Drug-Linker Conjugate for ADC
MC-Val-Cit-Doxorubicin is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound features a maleimide moiety, enabling conjugation with thiol-containing molecules. Doxorubicin, an anthracycline antibiotic, exhibits potent antineoplastic activity, making this conjugate a valuable tool for targeted cancer therapy research and development. -
Drug-Linker Conjugates for ADC Inhibitor
PSMA-Val-Cit-PAB-MMAE is a targeted drug-linker conjugate that utilizes monomethyl auristatin E (MMAE) to selectively inhibit prostate-specific membrane antigen (PSMA). This compound demonstrates potent cytotoxicity against PSMA-expressing tumor cells, making it a valuable tool for developing antibody-drug conjugates (ADCs) in prostate cancer therapy. Its design enhances the therapeutic efficacy while minimizing off-target effects in cancer treatment research. -
Drug-Linker Conjugate for ADC
VcMMAE-Deruxtecan is a targeted drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound combines a cytotoxic microtubule inhibitor, MMAE, with Exatecan, a DNA topoisomerase I inhibitor, facilitating precise targeting of cancer cells. VcMMAE-Deruxtecan is primarily utilized in the synthesis of ADCs, contributing to advancements in cancer therapeutics. -
Drug-Linker Conjugate for ADC
Aminocaproyl-Val-Cit-PABC-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound utilizes a cleavable linker to facilitate the selective release of the cytotoxic agent MMAE upon internalization and proteolytic cleavage, enhancing targeted delivery to cancer cells. It is suitable for research focused on developing and optimizing ADCs for therapeutic purposes in oncology. -
Drug-Linker Conjugate for ADC
GGFG-PAB-Exatecan is a drug-linker conjugate that combines the cytotoxic agent Exatecan with the linker GGFG-PAB. This compound is designed for the synthesis of antibody-drug conjugates (ADCs), facilitating targeted delivery of cytotoxic agents to cancer cells. Its unique structure can enhance the therapeutic efficacy of ADCs while minimizing off-target effects, making it a valuable reagent for cancer research and drug development applications. -
Drug-Linker Conjugates for ADC
Mal-Phe-C4-VC-PAB-MMAE is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound features monomethyl auristatin E (MMAE), a potent inhibitor of tubulin polymerization, which serves as the cytotoxic payload. Its structure is optimized for effective delivery and targeted therapy in cancer research, making it an essential reagent for developing and studying ADCs. -
Drug-Linker Conjugates for ADC
APL-1081 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). It features the Mal-Exo-EEVC peptide linker that facilitates effective targeting and delivery, combined with the potent tubulin polymerization inhibitor MMAE. This compound demonstrates significant biological activity by disrupting microtubule dynamics, making it valuable for research focused on cancer therapeutics and ADC development. -
Drug-Linker Conjugates for ADC
Mal-C2-Gly3-EDA-PNU-159682 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound features a cleavable linker, Mal-C2-Gly3-EDA, which facilitates the targeted delivery of the cytotoxic agent PNU-159682 to specific cells. Its robust structure allows for effective release of the potent cytotoxin upon internalization, making it suitable for cancer research and therapeutic development in targeted therapies. -
Drug-Linker Conjugate for ADC
DBCO-β-Glu-PEG12-Exatecan serves as a drug-linker conjugate specifically designed for antibody-drug conjugates (ADCs). This compound acts as a potent inhibitor of topoisomerase I, effectively disrupting DNA replication and transcription processes. Its unique structure allows for targeted delivery in therapeutic applications, making it suitable for research in cancer treatment and other malignancies. This reagent provides a valuable tool for the development and optimization of ADC formulations. -
Drug-Linker Conjugate for ADC
GGFG-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound consists of the GGFG-PAB linker, which facilitates targeted delivery, and the potent microtubule inhibitor MMAE, enhancing its therapeutic efficacy. GGFG-PAB-MMAE is utilized in research for developing effective cancer therapies through targeted cytotoxicity mechanisms. -
Drug-Linker Conjugates for ADC
Azido-PEG4-Val-Cit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It incorporates the potent anti-mitotic agent, monomethyl auristatin E (MMAE), via a cleavable linker that facilitates targeted delivery. This reagent features an azide group and is suitable for click chemistry reactions, specifically copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) with alkyne-containing molecules, as well as DBCO or BCN groups. Its use in ADC development underscores its significance in research focused on targeted cancer therapies. -
Drug-Linker Conjugate for ADC
Fmoc-GGFG-DXd is a drug-linker conjugate designed for antibody-drug conjugates (ADCs). It incorporates the Fmoc-GGFG linker and the potent DNA topoisomerase I inhibitor DXd. This compound is intended for use in targeted cancer therapies, facilitating the delivery of cytotoxic agents specifically to tumor cells while minimizing systemic toxicity. Its unique structure supports research in the development and optimization of ADC formulations for enhanced therapeutic efficacy. -
Drug-Linker Conjugates For ADC
Deruxtecan analog 2 is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound comprises Camptothecin, a well-known topoisomerase I inhibitor that exhibits potent antineoplastic activity against various cancers, including colorectal, breast, lung, and ovarian tumors. Deruxtecan analog 2 serves as a valuable reagent for the synthesis of anti-FGFR2 ADCs, advancing research in targeted cancer therapeutics. -
Drug-Linker Conjugates for ADC
SPP-DM1 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It utilizes DM1, a potent microtubule-disrupting agent, linked through the SPP linker to deliver targeted antitumor efficacy. This compound exhibits significant biological activity against malignant cells, making it relevant for cancer research and therapeutic development. SPP-DM1 is a valuable tool for studying the mechanisms of ADCs in oncology. -
Drug-Linker Conjugate for ADC
MC-VC-PABC-C6-α-Amanitin is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring the potent RNA polymerase IIα inhibitor α-Amanitin linked through a MC-VC-PABC-C6 linker. This compound exhibits significant cytotoxic activity against cancer cells by disrupting transcriptional processes. It is an essential tool for researchers focusing on targeted cancer therapies and ADC development. -
Drug-Linker Conjugate for ADC
LacNAc-VC-PAB-MMAE is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs). This compound is specifically engineered for attachment at the N-glycosylation site of Trastuzumab, utilizing WT Endo-S2 for assembly. LacNAc-VC-PAB-MMAE facilitates targeted delivery of cytotoxic agents, enhancing therapeutic efficacy in cancer treatment applications. Its innovative design supports research in ADC optimization and development for improved specificity and reduced systemic toxicity. -
Drug-Linker Conjugate for ADC
MCC-AAQ-Exa is a drug-linker conjugate designed for use in antibody-drug conjugates (ADCs), formed through the condensation of a linker with Exatecan. The MCC component features a maleimide fragment, facilitating efficient conjugation to antibodies. This reagent is essential for researchers developing targeted therapies, enabling the precise delivery of cytotoxic agents to tumor cells while minimizing systemic toxicity.
